GAMMA Investing
AVTX icon

GAMMA Investing’s Avalo Therapeutics AVTX Stock Holding History

GAMMA Investing’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.9K Buy
+189
New +$3.48K ﹤0.01% 3851

Other funds holding AVTX

PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Activest Wealth Management
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

GAMMA Investing's AVTX Position: Q3 2026 in Review

GAMMA Investing opened a new position in Avalo Therapeutics (AVTX) in Q3 2026: 189 shares worth $2.9K. The stake represents ﹤0.01% of the portfolio and ranks #3851 among its holdings.

10 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • GAMMA Investing held 189 shares of Avalo Therapeutics worth $2.9K as of Q3 2026.
  • Avalo Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Avalo Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3851 holding.
  • 10 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.